Anaplastic Large Cell Lymphoma Treatment Options

Anaplastic large cell lymphoma (ALCL) treatment options vary based on the specific type of ALCL, its stage, and your overall health. Treatment usually involves chemotherapy, often combined with targeted therapies like brentuximab vedotin. For some, radiation or stem cell transplant may be considered. Your care team will create a personalized plan to manage this rare non-Hodgkin lymphoma.

What is Anaplastic Large Cell Lymphoma Treatment Options?

Anaplastic large cell lymphoma (ALCL) treatment options are tailored to each person, considering the specific type of ALCL, how advanced it is, and individual health factors. This rare type of non-Hodgkin lymphoma primarily affects immune cells called T-cells. Treatment aims to eliminate cancer cells and manage symptoms, often involving a combination of therapies.

Anaplastic large cell lymphoma (ALCL) is a less common form of non-Hodgkin lymphoma, a cancer that starts in white blood cells called lymphocytes. These lymphocytes are part of your immune system. ALCL is categorized into different types, including systemic ALCL (sALCL), which affects lymph nodes and other organs, and primary cutaneous ALCL (pcALCL), which mainly affects the skin. The approach to treating ALCL depends significantly on whether the cancer cells have a specific genetic change called anaplastic lymphoma kinase (ALK) positivity. ALK-positive ALCL generally responds better to treatment than ALK-negative ALCL. Understanding these distinctions helps doctors choose the most effective therapies. Treatment plans are highly individualized and developed by a team of specialists.

Symptoms

Symptoms of anaplastic large cell lymphoma (ALCL) can vary depending on the type and location of the lymphoma. Common signs often include swollen, painless lymph nodes in areas like the neck, armpit, or groin. Some people may also experience general symptoms such as fever, night sweats, and unexplained weight loss, known as "B symptoms."

For systemic anaplastic large cell lymphoma (sALCL), the most common symptom is the enlargement of lymph nodes, which are small, bean-shaped glands that filter harmful substances. These swollen lymph nodes are usually painless. Other general symptoms, often called B symptoms, can include fevers that come and go, drenching night sweats, and losing weight without trying. About 1 in 3 people (30%) with sALCL experience these B symptoms. Primary cutaneous anaplastic large cell lymphoma (pcALCL), which affects the skin, typically presents as single or multiple skin lesions. These can appear as red or purplish bumps, nodules, or ulcers. Unlike sALCL, pcALCL often does not cause B symptoms or affect internal organs, making its presentation distinct. The specific symptoms guide the diagnostic process and treatment strategy.

Causes & risk factors

The exact causes of anaplastic large cell lymphoma (ALCL) are not fully understood, but it is not typically considered an inherited condition. Most cases arise without a clear reason. However, certain factors may increase risk, such as having a weakened immune system or, in rare instances, a specific type of breast implant, which is linked to breast implant-associated ALCL (BIA-ALCL).

Anaplastic large cell lymphoma (ALCL) is not caused by lifestyle choices or environmental exposures in most cases. It is also not contagious. Researchers believe that genetic changes within the T-cells, which are a type of white blood cell, lead to their uncontrolled growth and the development of ALCL. These changes are usually acquired during a person's lifetime rather than inherited. One specific risk factor identified is for a rare form called breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). This type of ALCL can develop in the scar tissue or fluid around breast implants, particularly textured implants. While still very rare, it's an important consideration for individuals with breast implants who develop symptoms like swelling or fluid collection around the implant. Other potential, though less defined, risk factors include certain immune system disorders or prior exposure to specific viruses, but these links are not as strong or consistent as the BIA-ALCL association.

How it's diagnosed

Diagnosing anaplastic large cell lymphoma (ALCL) typically begins with a physical exam and a review of your symptoms. The definitive diagnosis requires a biopsy, where a small tissue sample, often from a swollen lymph node or skin lesion, is removed and examined under a microscope. Further tests, such as imaging scans and blood tests, help determine the extent of the disease.

The most crucial step in diagnosing ALCL is a biopsy. During this procedure, a doctor removes a small piece of affected tissue, such as an entire lymph node or a part of a skin lesion. This sample is then sent to a pathologist, a doctor who specializes in diagnosing diseases by examining tissues and cells. The pathologist looks for specific features of ALCL cells and performs special tests, like immunohistochemistry, to identify markers such as CD30 and ALK protein. Once ALCL is confirmed, further tests are done to "stage" the cancer, meaning to find out if it has spread and to what extent. These staging tests may include blood tests, bone marrow biopsy (taking a sample of bone marrow for examination), and imaging scans like computed tomography (CT) scans, positron emission tomography (PET) scans, or magnetic resonance imaging (MRI). These tests help your care team understand the full picture of the disease and plan the most appropriate treatment.

Treatment options

Treatment for anaplastic large cell lymphoma (ALCL) is highly individualized and depends on the specific type, stage, and your overall health. For systemic ALCL, chemotherapy is often the primary treatment, sometimes combined with targeted therapy. Primary cutaneous ALCL, which is usually less aggressive, may be treated with surgery, radiation, or topical therapies.

For systemic anaplastic large cell lymphoma (sALCL), the initial treatment usually involves combination chemotherapy. A common regimen is CHOP, which includes cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisone. For ALK-negative sALCL, which can be more aggressive, targeted therapies like brentuximab vedotin (Adcetris) are often incorporated into the frontline treatment or used for relapsed disease. Brentuximab vedotin targets a protein called CD30, which is found on ALCL cells. If the ALCL is localized or has recurred in a specific area, radiation therapy might be used to shrink tumors and relieve symptoms. For some people, especially those with relapsed or refractory (not responding to initial treatment) sALCL, a stem cell transplant may be considered. This procedure involves high-dose chemotherapy followed by the infusion of healthy blood-forming stem cells, either from your own body (autologous) or a donor (allogeneic). Primary cutaneous anaplastic large cell lymphoma (pcALCL) often has a more favorable outlook and may require less intensive treatment. For single skin lesions, surgical removal or radiation therapy can be effective. For multiple or widespread skin lesions, topical treatments, low-dose methotrexate, or brentuximab vedotin may be used. Your doctor will discuss the best treatment approach based on your specific diagnosis and health needs.

Recovery & outlook

The recovery and outlook for anaplastic large cell lymphoma (ALCL) vary significantly based on the type of ALCL, its stage, and how well it responds to treatment. ALK-positive systemic ALCL generally has a better prognosis than ALK-negative systemic ALCL. Many people achieve remission, but long-term follow-up is essential due to the possibility of recurrence.

For people with ALK-positive systemic ALCL, the prognosis is generally favorable, with many achieving long-term remission. However, ALK-negative systemic ALCL can be more challenging to treat and may have a higher risk of recurrence. The overall outlook has improved with advancements in treatment, including targeted therapies like brentuximab vedotin, which have shown significant benefits, especially for relapsed disease. Primary cutaneous ALCL (pcALCL) typically has an excellent prognosis, with many cases responding well to local treatments and often having spontaneous regression (shrinking on its own). While pcALCL can recur, it rarely spreads to internal organs. Regular follow-up appointments, including physical exams and imaging, are crucial for all types of ALCL to monitor for any signs of recurrence or new symptoms. Your care team will help you understand your specific prognosis and what to expect during and after treatment.

When to see a doctor

You should see a doctor if you notice any persistent or unexplained symptoms that could indicate anaplastic large cell lymphoma (ALCL). This includes new, painless swollen lymph nodes, especially in the neck, armpit, or groin, or unexplained fevers, night sweats, or significant weight loss. Prompt medical evaluation is important for an accurate diagnosis and timely treatment.

It is important to contact your doctor if you experience any new or worsening symptoms that persist for more than a few weeks. While many conditions can cause swollen lymph nodes or general symptoms like fatigue, it's essential to rule out serious conditions like lymphoma. Do not delay seeking medical attention if you have concerns. Specifically, be alert for: * Swollen lymph nodes that are painless and do not go away. * Unexplained fevers, especially if they occur daily or nightly. * Drenching night sweats that soak your clothes or bedding. * Unintentional weight loss of more than 10% of your body weight over six months. * New or changing skin lesions, such as persistent lumps or ulcers, particularly if you have breast implants. These symptoms do not necessarily mean you have ALCL, but they warrant a thorough medical evaluation by a qualified clinician.

Frequently asked questions

What is the difference between ALK-positive and ALK-negative ALCL?

ALK-positive anaplastic large cell lymphoma (ALCL) means the cancer cells have a specific genetic change involving the ALK gene, which often makes them more responsive to treatment. ALK-negative ALCL lacks this gene change and can sometimes be more aggressive, requiring different treatment approaches.

Can anaplastic large cell lymphoma (ALCL) be cured?

Many people with anaplastic large cell lymphoma (ALCL), especially ALK-positive systemic ALCL and primary cutaneous ALCL, can achieve long-term remission, meaning the cancer is no longer detectable. While "cure" is a strong term, effective treatments can lead to excellent outcomes for many individuals.

What is brentuximab vedotin, and how does it work for ALCL?

Brentuximab vedotin (Adcetris) is a targeted therapy used for anaplastic large cell lymphoma (ALCL). It works by delivering a chemotherapy drug directly to cancer cells that have a specific protein called CD30 on their surface, which is common in ALCL cells. This helps to kill cancer cells while minimizing harm to healthy cells.

Is surgery an option for ALCL?

Surgery is primarily an option for primary cutaneous anaplastic large cell lymphoma (pcALCL) when it presents as a single skin lesion. For systemic ALCL, surgery is generally not a primary treatment, but a biopsy is essential for diagnosis.

What are the common side effects of ALCL chemotherapy?

Common side effects of chemotherapy for anaplastic large cell lymphoma (ALCL) can include fatigue, nausea, hair loss, mouth sores, and a weakened immune system, which increases the risk of infection. Your care team will help manage these side effects.

How often do I need follow-up appointments after ALCL treatment?

After treatment for anaplastic large cell lymphoma (ALCL), regular follow-up appointments are crucial. The frequency will depend on your specific type of ALCL, the treatment received, and your response, but typically involves physical exams and imaging scans every few months initially, gradually becoming less frequent over time.

Sources

• MedlinePlus — Anaplastic Large Cell Lymphoma Treatment Options
• Mayo Clinic — Anaplastic Large Cell Lymphoma Treatment Options
• Cochrane Library — Anaplastic Large Cell Lymphoma Treatment Options